Independent Validation of a Prognostic Genomic Signature (ColoPrint) for Patients With Stage II Colon Cancer

Maak, Matthias; Simón, Iris; Nitsche, Ulrich; Roepman, Paul; Snel, Mireille H.J.; Glas, Annuska M.; Schuster, Tibor; Keller, Gisela; Zeestraten, Eliane C.M.; Goossens, Inès; Janssen, Klaus–Peter; Friess, Helmut; Rosenberg, Robert D.

doi:10.1097/sla.0b013e31827c1180

Cited by 107 publications

(80 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Microsatellite stability status was determined as described previously (25,26). For the discovery study cohort, we included only histologically proven TNM stage II-III first primary colorectal carcinomas of the microsatellite stable phenotype, of patients who did not receive preoperative treatment.…”

Section: Study Cohortmentioning

confidence: 99%

MicroRNA Classifier and Nomogram for Metastasis Prediction in Colon Cancer

Goossens-Beumer

Derr

Buermans

et al. 2015

Cancer Epidemiology, Biomarkers &Amp; Prevention

Self Cite

View full text Add to dashboard Cite

Background: Colon cancer prognosis and treatment are currently based on a classification system still showing large heterogeneity in clinical outcome, especially in TNM stages II and III. Prognostic biomarkers for metastasis risk are warranted as development of distant recurrent disease mainly accounts for the high lethality rates of colon cancer. miRNAs have been proposed as potential biomarkers for cancer. Furthermore, a verified standard for normalization of the amount of input material in PCR-based relative quantification of miRNA expression is lacking.Methods: A selection of frozen tumor specimens from two independent patient cohorts with TNM stage II-III microsatellite stable primary adenocarcinomas was used for laser capture microdissection. Next-generation sequencing was performed on small RNAs isolated from colorectal tumors from the Dutch cohort (N ¼ 50). Differential expression analysis, comparing in metastasized and nonmetastasized tumors, identified prognostic miRNAs.

show abstract

Section: Study Cohortmentioning

confidence: 99%

MicroRNA Classifier and Nomogram for Metastasis Prediction in Colon Cancer

Goossens-Beumer

Derr

Buermans

et al. 2015

Cancer Epidemiology, Biomarkers &Amp; Prevention

Self Cite

View full text Add to dashboard Cite

show abstract

“…com) is an 18-gene expression signature that was developed based on unbiased gene selection, searching the whole genome for genes that have the highest correlation to a tumor-relapse event [19]. The signature was translated into a diagnostic test, validatedin three independentstudies [19][20][21], andshown to be technically reproducible and robust [20]. In this study, we described the pooled analysis of all stage II patients from the independent cohorts of patients treated in the U.S., Spain, Germany, Italy, and Austria.…”

Section: Introductionmentioning

confidence: 99%

Genomic Classifier ColoPrint Predicts Recurrence in Stage II Colorectal Cancer Patients More Accurately Than Clinical Factors

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…Prognostic potential independent of many of the high-risk factors of stage II colon cancer has been shown retrospectively for these tests by multivariate validation analyses. Also, independence of MSI status has been validated for Oncotype DX Colon Cancer (33,35) and ColoPrint (46,47). Importantly, among the secondary objectives of the PARSC trial is comparison of risk assessment according to ColoPrint and the American Society of Clinical Oncology high-risk criteria (2).…”

Section: Clinical Potentialmentioning

confidence: 99%

Anticipating the Clinical Use of Prognostic Gene Expression–Based Tests for Colon Cancer Stage II and III: Is Godot Finally Arriving?

Sveen

Nesbakken

Ågesen

et al. 2013

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: According to current recommendations for adjuvant treatment, patients with colon cancer stage II are not routinely offered chemotherapy, unless considered to have a high risk of relapse based on specific clinicopathological parameters. Following these criteria, it is challenging to identify the subgroup of patients that will benefit the most from adjuvant treatment. Contrarily, patients with colon cancer stage III are routinely offered chemotherapy, but due to expected adverse effects and frailty, elderly patients are often excluded from standard protocols. Colon cancer is a disease of the elderly and accordingly, there is a large subgroup of patients for which guidelines for adjuvant treatment remain less clear. In these two clinical settings, improved risk stratification has great potential impact on patient care, anticipating that high-risk patients will benefit from chemotherapy. However, microsatellite instability is the only molecular prognostic marker recommended for clinical use.Experimental Design: In this perspective, we provide an updated view on the status and clinical potential of the many proposed prognostic gene expression-based tests for colon cancer stage II and III.Results: The main limitation for clinical implementation is lack of prospective validation. For patients with stage II, highly promising tests have been identified and clinical trials are ongoing. For elderly patients with stage III, the value of such tests has received less focus, but promising early results have been shown.Conclusion: Although awaiting results from prospective trials, improved risk assessment for patients with stage II and III is likely to be achieved in the foreseeable future.

show abstract

Independent Validation of a Prognostic Genomic Signature (ColoPrint) for Patients With Stage II Colon Cancer

Abstract: ColoPrint is able to predict the development of distant metastasis of patients with stage II colon cancer and facilitates the identification of patients who may be safely managed without chemotherapy.

Cited by 107 publications

References 32 publications

MicroRNA Classifier and Nomogram for Metastasis Prediction in Colon Cancer

MicroRNA Classifier and Nomogram for Metastasis Prediction in Colon Cancer

Genomic Classifier ColoPrint Predicts Recurrence in Stage II Colorectal Cancer Patients More Accurately Than Clinical Factors

Anticipating the Clinical Use of Prognostic Gene Expression–Based Tests for Colon Cancer Stage II and III: Is Godot Finally Arriving?

Contact Info

Product

Resources

About